|  |  | 

India Top Headlines

Zydus Cadila’s Virafin Granted Emergency Restricted Use Approval for Treatment of Covid Patients: DBT | India News


NEW DELHI: The Comptroller General of Medicines of India (DCGI) has granted emergency restricted use approval to Zydus Cadila’s Virafin for the treatment of patients showing moderate symptoms of Covid-19, the biotechnology department said on Saturday.
Virafin is a pegylated interferon alpha-2b (PegIFN), which when injected subcutaneously into the patient in the early stages of infection, results in a faster recovery, he said.
Studies confirmed the safety, tolerability, and efficacy of Virafin. Studies also reported that Viarfin reduces viral load and helps manage disease in better ways, such as reducing the need for supplemental oxygen, thereby reducing respiratory tension caused by low oxygen levels, the DBT said.
Zydus Cadila had said on Friday that it had received emergency restricted-use approval from India’s drug regulator for the use of pegylated interferon alfa-2b (PegIFN) in the treatment of moderate Covid-19 infection in adults.
Renu Swarup, Secretary, DBT and President of the Biotechnology Industry Research Assistance Council (BIRAC) said: “The government is committed to providing all possible facilitation to our industries to work towards mitigation strategies and interventions against the Covid-19 pandemic “.
The emergency nod provided to Virafin is another milestone that is a boon for medical facility providers, he noted.

Times of India